Pfizer, Inc. (PFE) News
Pfizer, Inc. (PFE)
Today's Latest Price: $36.23 USD
Updated Jan 21 1:28pm
Add PFE to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
StocksNews Articles for PFE
| Date | Symbol | Company | Title | Start | End | Change | POWR Rating | ||
|---|---|---|---|---|---|---|---|---|---|
| Loading, please wait... | |||||||||
Latest PFE News From Around the Web
Below are the latest news stories about Pfizer Inc that investors may wish to consider to help them evaluate PFE as an investment opportunity.
Some COVID-19 variants may reduce effectiveness of vaccinesScientists are reporting troubling signs that some recent mutations of the virus that causes COVID-19 may modestly curb the effectiveness of two current vaccines, although they stress that the shots still protect against the disease. |
Pfizer (PFE) Stock Sinks As Market Gains: What You Should KnowPfizer (PFE) closed at $36.50 in the latest trading session, marking a -0.63% move from the prior day. |
Pfizer Says Covid Jab Could Battle U.K. Variant; Gritstone Expands Its GainVaccine stocks Pfizer and BioNTech dipped Wednesday after test results in the blood of vaccinated people showed their vaccine could protect humans against the U.K. variant of Covid-19. |
COVID SCIENCE-S. African virus variant may resist antibody drugs; Pfizer/BioNTech vaccine seems to work vs UK variantThe following is a roundup of some of the latest scientific studies on the novel coronavirus and efforts to find treatments and vaccines for COVID-19, the illness caused by the virus. The variant of the new coronavirus identified in South Africa can resist, or "escape," antibodies that neutralize earlier versions of the virus, scientists have found. It "exhibits complete escape" from three classes of monoclonal antibodies manufactured for treating COVID-19 patients, and it shows "substantial or complete" resistance to neutralizing antibodies in blood donated by COVID-19 survivors, the scientists reported on Tuesday on bioRxiv ahead of peer review. |
Gilead Stock 2021: Why The Biotech Stock Isn't Depending On Covid DrugsGilead Sciences isn't betting its 2021 on coronavirus treatment Veklury. But the biotech company still sees plenty of catalysts in oncology, virology and inflammation for Gilead stock. |
Ivory Coast says delivery of its first doses of Pfizer vaccine delayed to mid-FebIvory Coast's government said it will receive a first batch of around 100,000 doses of the Pfizer BioNTech coronavirus vaccine in mid February, around two weeks later than initially planned, due to delays in availability of the shots. Government spokesman Sidi Tiemoko Toure said on Wednesday the country plans to roll out its inoculation programme in the first quarter and would authorise vaccines from AstraZeneca , China's Sinopharm and Russia this week. While richer nations have secured and launched mass vaccination campaigns, countries in Africa are still scrambling to secure supplies as most grapple with a second wave of infections. |
Three COVID-19 vaccines under final review for emergency use - WHOThe World Health Organization (WHO) said on Wednesday that three COVID-19 vaccines were in the late stages of review for possible emergency use listing, in addition to the one made by Pfizer and BioNTech already approved. The WHO was not aware of any deaths linked to the Pfizer vaccine, nor any other vaccine, she added. |
Biden Agenda, Intel Profit, Jobless Claims: 3 Things to WatchBy Liz Moyer |
Pfizer-BioNTech Vaccine Found Effective Against New Coronavirus Strain In Lab StudyThe coronavirus vaccine developed by Pfizer Inc. (NYSE: PFE) and BioNTech SE - ADR (NASDAQ: BNTX) works against a new strain of coronavirus that appeared in the U.K., according to a preprint made available before publication.What Happened: The B.1.1.7 strain is unlikely to escape BNT162b2-mediated protection, according to the preprint. BNT162b2 is the mRNA-based vaccine developed by Pfizer-BioNTech and is approved for emergency use in a host of countries.The deduction followed investigation of SARS-CoV-2 pseudoviruses bearing either the Wuhan reference strain or the B.1.1.7 lineage spike protein with sera of 16 participants in a previously reported trial with BNT162b2.The immune sera had equivalent neutralizing titers to both variants, and it also provided combined immunity involving... |
Gritstone (GRTS) to Begin Coronavirus Vaccine Study, Stock UpGritstone (GRTS) will develop a second generation vaccine candidate against COVID-19 with the potential for both prolonged protection and potency against spike mutants of the virus. Stock rises. |